Bio Nucleus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 20 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -22.73%
- Profit Growth 146.96%
- Ebitda 41.51%
- Net Worth 1.30%
- Total Assets -21.18%
About Bio Nucleus Pharmaceuticals
Bio Nucleus Pharmaceuticals Private Limited (BNPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 January 2015 and has a history of Ten years. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Supriya Verma and Kumar Prashant serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U33110DL2015PTC275677
-
Company No.
275677
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Jan 2015
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Bio Nucleus Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Supriya Verma
|
Director | 30-Sep-2021 | Current |
|
Kumar Prashant
|
Director | 01-Feb-2018 | Current |
Financial Performance of Bio Nucleus Pharmaceuticals.
Bio Nucleus Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 22.73% decrease. The company also saw a substantial improvement in profitability, with a 146.96% increase in profit. The company's net worth moved up by a moderate rise of 1.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio Nucleus Pharmaceuticals?
In 2018, Bio Nucleus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Adventure Turnkey Solutions Private LimitedSupriya Verma is a mutual person
-
Dream Holiday Solutions Private Limited
Supriya Verma is a mutual person
-
Karna's Foundation
Supriya Verma is a mutual person
-
Byder Solutions Private Limited
Kumar Prashant is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bio Nucleus Pharmaceuticals?
Unlock and access historical data on people associated with Bio Nucleus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio Nucleus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio Nucleus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
